Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

5 Customer Reviews

  • Tumors were resected from mice 10 days after orthotopic inoculation of 4T1-Luc2 cells, and hydrogels loaded with the following payloads were evaluated: anti–PD-1, anti-CTLA-4, IL-15sa, lenalidomide, celecoxib, STING-RR, or R848. Mice that did not receive a hydrogel were examined as a negative control. (A) IVIS imaging of 4T1-Luc2 cells is shown for all groups described and illustrates tumor burden.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Celecoxib purchased from Selleck.

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

  • Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

  • Oncol Lett, 2018, 16(1):317-325. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NE\jXXlHfW6ldHnvckBCe3OjeR?= M{\pdVAvOS1|MDFOwG0> NIK4XmQ1QCCq MWTpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> Ml\XNlY2OTNzN{K=
H460 MkTmSpVv[3Srb36gRZN{[Xl? Mn2zNE4yNTNyIN88US=> NHizVmM1QCCq MmDHbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> MXOyOlUyOzF5Mh?=
HKESC-2 NGDp[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKxNlDDqM7:TR?= NHTFSlc1QMLiaNMg NXLNSXFYe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi M1\iZVI3PDd2Nkmz
CaES-17 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXZNlDDqM7:TR?= MW[0POKhcMLi NIP5VWJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? NUHKdXkzOjZ2N{S2PVM>
HKESC-2 MX;BdI9xfG:|aYOgRZN{[Xl? NHzIVVkzOMLizszN NH\GRWY1QMLiaNMg NH\Db5Zz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MV6yOlQ4PDZ7Mx?=
CaES-17 NX7V[3pySXCxcITvd4l{KEG|c3H5 NHP4TnozOMLizszN NYH6V3JuPDkEoHlCpC=> NETzVFBz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MmPrNlY1PzR4OUO=
A549 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jvbFUuOTZyIN88US=> M37ES|Q5yqCqwrC= NV3OVo1JTE2VTx?= MoH5TWM2OD1zNkOuOEDPxE1? Ml36NlY1PjR4NEO=
HCC827 M37L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzCfHc2NTF4MDFOwG0> MnHSOFjDqGkEoB?= NYHaU3RrTE2VTx?= MmfMTWM2OD14OT6yJO69VQ>? M1jHRlI3PDZ2NkSz
A549 M2PEVWFxd3C2b4Ppd{BCe3OjeR?= NYXRUXY4QDBiwsXN MnrUOFjDqGkEoB?= MkLZSG1UVw>? MYrpcoR2[2W|IHHwc5B1d3Orcx?= M1nXRlI3PDZ2NkSz
HCC827 MX\BdI9xfG:|aYOgRZN{[Xl? NWfzc4pLQDBiwsXN MV60POKhcMLi MmPrSG1UVw>? MnLLbY5lfWOnczDhdI9xfG:|aYO= M{[0RVI3PDZ2NkSz
SGC-7901/DDP NVnDR5pETnWwY4Tpc44hSXO|YYm= MVmxNOKhyrWP MX6yOEBp M4fZfolvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MnPNNlY1ODd4NUO=
SGC-7901  Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ldVI1yqCqwrC= M3jkWmlEPTB;MUG1MlA5KM7:TR?= MlLKNlY1ODd4NUO=
SGC-7901/DDP MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCwNlTDqGkEoB?= MVzJR|UxRTN3LkS1JO69VQ>? NWfZeXlnOjZ2MEe2OVM>
SGC-7901/DDP M4rSTmFxd3C2b4Ppd{BCe3OjeR?= MkjYNVDDqML3TR?= MmjvNlQhcA>? NWn2R|d6cW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDD3bZRpKGOrc4DsZZRqdg>? MUGyOlQxPzZ3Mx?=
SGC-7901/DDP NWTrSWh4TnWwY4Tpc44hSXO|YYm= MWmxNOKhyrWP MVmyOEBp MoXvbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB? MV6yOlQxPzZ3Mx?=
SGC-7901/DDP NXfRNXY4TnWwY4Tpc44hSXO|YYm= NUDqWXU6OTEEoNM1US=> M17kcVI1KGh? NFe0dWJk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> MljoNlY1ODd4NUO=
H357 NG\1eotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPpT2V[Py53L{GwJO69VQ>? MWi0PEBp NITSOGNFVVOR MWjpcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4 M2HFXlI3ODB7OEe0
TAF MkfqSpVv[3Srb36gRZN{[Xl? NHTEUIQyOMLiwsXN NWDpbZJFPyCm NUjHVFBU[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= MXuyOVk5PzF{Nx?=
TAF MWfGeY5kfGmxbjDBd5NigQ>? MWWxNOKhyrWP MkTKN|AuOTJyIH3pci=> M1XiNZBwd3KueTDh[oZm[3S|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=> NVX6PI17OjV7OEexNlc>
TAF NYnyS4lvTnWwY4Tpc44hSXO|YYm= M4KxOFExyqEEtV2= NXP2UYh4PDhiaB?= MXPpcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? Mo\YNlU6QDdzMke=
PANC-1 NVnUU4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmxNlAwPjBxMUCwJO69VQ>? MVKyOE81QC95MjDo M17DZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MmD3NlU6PzNyNkK=
PANC-1 NYK4bY04TnWwY4Tpc44hSXO|YYm= NEnIeIUzOC94MD:xNFAh|ryP M2LwfVI1KGh? M1SzOIF1fGWwdXH0d{Bk\WyuIHnueoF{cW:wIHHu[EBucWe{YYTpc44hcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NXTRTHpjOjV7N{OwOlI>
HeLa  MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSyNOKh|ryPwrC= M3HVOlI1yqCq MoC1[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NXzjcpQ6OjV5N{C0NlM>
SACC-83 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOyNOKh|ryPwrC= MomyNlTDqGh? MUPlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NXnGNIgyOjV5N{C0NlM>
HeLa  NYjiNZo4SXCxcITvd4l{KEG|c3H5 NHfzbWEzOMLizszNxsA> MWCyOOKhcA>? M1jaWoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> MmPRNlU4PzB2MkO=
SACC-83 NUPEWG5MSXCxcITvd4l{KEG|c3H5 NWLOb5k5OjEEoN88UeKh NYDuSoNyOjUEoHi= M2TEZoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> MWeyOVc4ODR{Mx?=
HeLa  M3ux[GZ2dmO2aX;uJGF{e2G7 MXWyNE81OC96MDFOwG0> NY\ueWxkOjUEoHi= NX3zNWxWfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? NWWxTItGOjV5N{C0NlM>
SACC-83 MlXwSpVv[3Srb36gRZN{[Xl? MnrFNlAwPDBxOECg{txO NIjqZ2YzPMLiaB?= Mlz2eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> NV;PNXJOOjV5N{C0NlM>
HLCZ01 M{XiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rMXlDjiJN4MNMgxtVO MUC0PEBp MWPEUXNQ M4CzZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M4X1clI2PzJ2OEm5
HLCZ01 NX33NnFVTnWwY4Tpc44hSXO|YYm= NFLwfGM1OMLizszN M2fvUVI1KGh? M1fVdmROW09? M4nZe4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MlS3NlU4OjR6OUm=
HLCZ01 MlzqRZBweHSxc3nzJGF{e2G7 NHXhTFc1OMLizszN NXLDOFNxOjRiaB?= NU\hZVRUTE2VTx?= MojM[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y NYLjSJdbOjV5MkS4PVk>
HLCZ01 MWPGeY5kfGmxbjDBd5NigQ>? NFrHbIs1OMLizszN M2S5VVI1KGh? NED6[IdFVVOR M2TXWolv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> M4i0WlI2PzJ2OEm5
MGC803 M{e4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PKVVAuPjBizszN NEiwSGQ4OiCq NUT4W413UUN3ME20O{4zPeLCidMx5qCKPi52MzFOwG0> MnXkNlU4ODF|N{i=
SGC7901 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HoOVAuPjBizszN NFP4cmQ4OiCq NV7YW2l{UUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> MYqyOVcxOTN5OB?=
MGC803 MojtSpVv[3Srb36gRZN{[Xl? M335b|QxyqEQvF2= MoL2PE8yPi9{NDDo M1XBbpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> M13BelI2PzBzM{e4
SGC7901 NGfQTY9HfW6ldHnvckBCe3OjeR?= NU[2WYFbPDEEoN88US=> M2m2fVgwOTZxMkSgbC=> NUX3O4t3fXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v MVGyOVcxOTN5OB?=
MCF-7  M{XxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHwNU8yOCEQvF2= NVTaXVdoPzJiaB?= M4PI[mROW09? NGf2e2VmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= NIHYPW4zPTZ4N{WxNC=>
MDA-MB-231  NGfNfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK3R|V[OS9zMDFOwG0> MUK3NkBp NHfET3BFVVOR Mk\V[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? M1nrXFI2PjZ5NUGw
MDA-MB-231 MoL4SpVv[3Srb36gRZN{[Xl? MXKwMVQxKML3TR?= M4fkdlQuOjRiaB?= NGDFTmJqdmO{ZXHz[ZMhS0:[LUKgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz NEDSOYUzPTV6N{OyPS=>
MCF-7 NEjW[HdHfW6ldHnvckBCe3OjeR?= NU\hfHpNOC12MDFCuW0> MlK4OE0zPCCq Mo\j[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? M2LYOVI2PTh5M{K5
MCF7-MX  M2DYRmZ2dmO2aX;uJGF{e2G7 NV70SWZPOC12MDFCuW0> NXzBepd3PC1{NDDo NW[zc2N6\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= MWOyOVU5PzN{OR?=
MDA-MB-231 NWfJWYRFTnWwY4Tpc44hSXO|YYm= MVSwMVQxKML3TR?= NFq0[Ig1NTJ2IHi= NHjkNXl{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= M1H0UVI2PTh5M{K5
A2780 NH;aZVlHfW6ldHnvckBCe3OjeR?= MkXWOU8yOC9zNTFOwG0> M3;jflQ5KGh? M4Cx[oRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NF[y[4MzPTR{NEi5PC=>
SKOV3  MYjGeY5kfGmxbjDBd5NigQ>? NWPtfWJZPS9zMD:xOUDPxE1? MYS0PEBp MVXk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mm\5NlU1OjR6OUi=
A2780 NYfvTGFKTnWwY4Tpc44hSXO|YYm= NFjpfI02NzFyL{G1JO69VQ>? MnW2OFghcA>? NVHINFll\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= NVfJe|ZIOjV2MkS4PVg>
SKOV3  NFP2TWxHfW6ldHnvckBCe3OjeR?= MUi1M|ExNzF3IN88US=> Mly3OFghcA>? NHHId4NmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw NEfwZmYzPTR{NEi5PC=>
A2780 NETmTZRHfW6ldHnvckBCe3OjeR?= MWS1M|ExNzF3IN88US=> NVrOfG9vPDhiaB?= NYrLbVk{\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu MU[yOVQzPDh7OB?=
SKOV3  NHexTGRHfW6ldHnvckBCe3OjeR?= NV3JNWFFPS9zMD:xOUDPxE1? NGG2XYI1QCCq Mnnx[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw M4fzeVI2PDJ2OEm4
A2780 NIK3PXpHfW6ldHnvckBCe3OjeR?= NIO4V242NzFyL{G1JO69VQ>? NXzLNHA3OSCq MYXpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M176U|I2PDJ2OEm4
SKOV3  MX7GeY5kfGmxbjDBd5NigQ>? NEi3d3M2NzFyL{G1JO69VQ>? NGrPSZcyKGh? Mk\4bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NH\WcJAzPTR{NEi5PC=>
HCT-15 MlnUSpVv[3Srb36gRZN{[Xl? NGP1bW8yOC13MDFOwG0> MWm2MVM3KGh? MYPpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NWnXVVZjOjV{MUiwNlg>
HT-29  NVrR[YkzTnWwY4Tpc44hSXO|YYm= NWTqUGdSOTBvNUCg{txO MkTiOk0{PiCq NXfpdFlIcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NEfVcngzPTJzOECyPC=>
HSC3  NGnNTlVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MU[w5qCUPDBizszN MnuxOFghcA>? NUXIbFJlUUN3ME2yOU42yrFzLke4NEDPxE1? MYmyOVE6QDd6OR?=
HSC3  M1zmXGFxd3C2b4Ppd{BCe3OjeR?= MnLnNlUh|ryP NXnQW41KPDhiaB?= MnfJbY5lfWOnczDhdI9xfG:|aYO= M4LUe|I2OTl6N{i5
HSC3  NYPnbmVDTnWwY4Tpc44hSXO|YYm= MljrNlUh|ryP MnmxOFghcA>? MW\lfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV M370cVI2OTl6N{i5
HSC3  NWLnR5hWTnWwY4Tpc44hSXO|YYm= MX:yOUDPxE1? M{nrS|Q5KGh? M4jMZ4lvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> MUiyOVE6QDd6OR?=
HSC3  MoTwSpVv[3Srb36gRZN{[Xl? NV3FRodUOjVizszN MYO3NkBp MVjk[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= MVeyOVE6QDd6OR?=
201T  NY\TXWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DIclczKGh? NETnWYtFVVOR M3;hZWlEPTB;NEiuOkDDvU1? MW[yOVA2Pzl2MR?=
273T NGftVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe3NkBp MlP3SG1UVw>? M2LCOmlEPTB;OECuOUDDvU1? MnftNlUxPTd7NEG=
Hep-2 M4rtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSzNE82OC9zMECg{txO NFTobnYyOi9{ND:zOk81QCCq MmnmSG1UVw>? NYfOdZA5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NX3mfoVIOjR7OUi1OlQ>
Hep-2 M4TIVmFxd3C2b4Ppd{BCe3OjeR?= MnLoOVAh|ryP NVm1S4dEOC12ODDo NV3BdY45TE2VTx?= NELrbYNqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MXSyOFk6QDV4NB?=
Hep-2 NYDNfFB{TnWwY4Tpc44hSXO|YYm= MVe1NEDPxE1? NUK2TZJFOC12ODDo NWTFRphETE2VTx?= MkPldoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? NIfVN2MzPDl7OEW2OC=>
Hep-2 NWn0e|NvTnWwY4Tpc44hSXO|YYm= MVu1NEDPxE1? NF;I[HcxNTR6IHi= Mo\pSG1UVw>? NXPYZWI3\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? NUPOc2pUOjR7OUi1OlQ>
SGC-7901 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n5N|ExNzVyL{GwNEDPxE1? M{naelI1NzR6L{eyJIg> MnrxSG1UVw>? MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXnROXZOOjR7OUK5OVg>
MKN-45 M170ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWxNE82OC9zMECg{txO MWSyOE81QC95MjDo MUTEUXNQ MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NYSzNItTOjR7OUK5OVg>
SGC-7901 M3Xub2Z2dmO2aX;uJGF{e2G7 MY[xNE82OC9zMECg{txO M3qxU|Q5KGh? MYXEUXNQ MVLkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MoHDNlQ6QTJ7NUi=
MKN-45 MY\GeY5kfGmxbjDBd5NigQ>? NXPhfHlYOTBxNUCvNVAxKM7:TR?= NELXTo81QCCq MUjEUXNQ MoP3[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWqyOFk6Ojl3OB?=
C666-1 NX72Rot1S3m2b4TvfIlkcXS7IFHzd4F6 MYKyNE05OCEQvF2= Ml:xNlQhcA>? MXXk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NYXNcGRrOjR6NUS4N|g>
CNE-1 M1S0eWN6fG:2b4jpZ4l1gSCDc4PhfS=> MmHuNlAuQDBizszN NHXnfIYzPCCq MUXk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MWGyOFg2PDh|OB?=
CNE-2 M{DxTmN6fG:2b4jpZ4l1gSCDc4PhfS=> MmrrNlAuQDBizszN NWPmXGp1OjRiaB?= Mly0[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> M2HZdlI1QDV2OEO4
C666-1 MoTIR5l1d3SxeHnjbZR6KEG|c3H5 MlixOlAh|ryP MV23JIQ> NX3ZcW1S\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> M{S1WlI1QDV2OEO4
CNE-1 MkOyR5l1d3SxeHnjbZR6KEG|c3H5 NEXLVos3OCEQvF2= NYjXWXdFPyCm NUL0SZBn\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NHvFTo0zPDh3NEizPC=>
SNU-1041 NUTncZk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfvSYdvOC12MDFOwG0> M13QOlQ5KGh? MlqxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MkjrNlQ3QTJ5MEO=
SNU-1041 MUXGeY5kfGmxbjDBd5NigQ>? NVHH[29iOjBxM{Cg{txO NUjt[YZTPCCq MmjCbY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> M2fBXVI1Pjl{N{Cz
SNU-1041 NXiwfm11TnWwY4Tpc44hSXO|YYm= MVewMVQxKM7:TR?= NHHFdVY1KGh? MUn1dE1z\We3bHH0[ZMhS0iRUNMgZYZ1\XJidILlZZRu\W62IIfpeIghcGmpaDDjc45k\W62cnH0bY9vew>? MXKyOFY6OjdyMx?=
SGC-7901 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjXVIg2OC1zMkWg{txO NUnJSlI5OjRxNEivO|IhcA>? NVfUclhLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NH\6do8zPDZ5NkO5OC=>
SGC-7901 MofjRZBweHSxc3nzJGF{e2G7 NHfkOVEyODBizszN NWmxSIExPzJiaB?= MXnpcoR2[2W|IHHwc5B1d3Orcx?= MmHBNlQ3PzZ|OUS=
SGC-7901 NVO1N|ZbTnWwY4Tpc44hSXO|YYm= MnvQO|UwOTByL{GyOUDPxE1? M1ThVVI1NzR6L{eyJIg> MYrpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?= NEXEXGEzPDZ5NkO5OC=>
LMeC  NGjzSo1HfW6ldHnvckBCe3OjeR?= M3riWlIxNzVyIN88US=> M2XXblQ5KGh? NHzhTXRl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= NWnlZVljOjR4NU[3OFY>
CMeC-1 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4fzUVIxNzVyIN88US=> NYrTeW9WPDhiaB?= MoXHbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWntPY5zOjR4NU[3OFY>
LMeC NVnLUmlnS2WubDDWbYFjcWyrdImgRZN{[Xl? NYrpeFRPOjBxNUCg{txO NIjqO2k1QCCq Mlf4bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlSyNlQ3PTZ5NE[=
CMeC-1 NED2dWVHfW6ldHnvckBCe3OjeR?= NUDPVGJuOjBxNUCg{txO MlHGOFghcA>? MkjvbY5lfWOnczDHNU1UKGG{cnXzeC=> MoG1NlQ3PTZ5NE[=
LMeC MX7GeY5kfGmxbjDBd5NigQ>? M3fLWFIxNzVyIN88US=> M2Lzd|Q5KGh? NEnXWWtqdmS3Y3XzJGcyNVNiYYLy[ZN1 NIO0T2UzPDZ3Nke0Oi=>
CMeC-1 NX:yW5dWTnWwY4Tpc44hSXO|YYm= MUGyNE82OCEQvF2= MXS0PEBp NWXxc2RK\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUeyOFY2Pjd2Nh?=
LMeC MlHaSpVv[3Srb36gRZN{[Xl? MXuyNE82OCEQvF2= MkDVOFghcA>? NVe0OmlQ\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYn1RoxPOjR4NU[3OFY>
CMeC-1 NX:2[5FQTnWwY4Tpc44hSXO|YYm= MXmyNE82OCEQvF2= NX61S5VzPDhiaB?= M{HGeolv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> MXqyOFY2Pjd2Nh?=
LMeC MlX6SpVv[3Srb36gRZN{[Xl? M{\TO|IxNzVyIN88US=> MlTvOFghcA>? MUfpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u MWCyOFY2Pjd2Nh?=
OVCAR-3 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWDaN446OTBiwsXN M2nNSFEhcA>? MWTlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg NIfHXHgzPDV{MEKyOy=>
OVCAR-3 MV\BdI9xfG:|aYOgRZN{[Xl? Mn3iNVAhyrWP NFjNfo0yKGh? MUPwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> MmK1NlQ2OjB{Mke=
OVCAR-3 MX\GeY5kfGmxbjDBd5NigQ>? NXrSXHJEOTBiwsXN NVyzR21zOSCq M4TaWYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg MUKyOFUzODJ{Nx?=
OVCAR-3 NWG1W|Y2TnWwY4Tpc44hSXO|YYm= NYfLNGdkOTBiwsXN MYmxJIg> M1yxU4Rwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> NEnqVY4zPDV{MEKyOy=>
OVCAR-3 M3ewfWZ2dmO2aX;uJGF{e2G7 NIrkXGEyOCEEtV2= NIDoU3AyKGh? M4XaNYlvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v Ml7RNlQ2OjB{Mke=
CF33 MUTGeY5kfGmxbjDBd5NigQ>? MoDsNVAxKM7:TR?= M3fTWVI1KGh? NIWyRoJqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NFn6TZAzPDVyM{e4Ni=>
CF33 NXvJZW5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHI[4kyOC1zMECg{txO M2HYfVAuPCCm M3P3eYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlTJNlQ2ODN5OEK=
CF33 M4\WNWZ2dmO2aX;uJGF{e2G7 M{XRVlExNTFyMDFOwG0> MkjIOE0zPCCq MnnT[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1 MmnPNlQ2ODN5OEK=
LNCaP NYL1UVRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q3TVIwPS9zMDFOwG0> Mn\GPVYhcA>? NXr5WJh7cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MYCyOFI6Pjl5OB?=
LNCaP M3W5[mFxd3C2b4Ppd{BCe3OjeR?= Ml;5Nk82NzFyIN88US=> M{nkV|k3KGh? NHzGcYRqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MXeyOFI6Pjl5OB?=
PC-3  MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rudlAuPTBizszN NXTyfW5pPDkkgJno NU[zZ|FqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWixcm5kOjRzMke4PFI>
PC-3  M1L3fmNmdGxiVnnhZoltcXS7IFHzd4F6 NWTZVppvOC1zMECg{txO M3j3WVczKGh? NU\ROZdk\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MWeyOFEzPzh6Mh?=

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT01344200 Not yet recruiting Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT03850587 Not yet recruiting Osteoarthritis Knee Yooyoung Pharmaceutical Co. Ltd.|Green Cross Corporation March 3 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products4

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID